CN105250368B - It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application - Google Patents
It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application Download PDFInfo
- Publication number
- CN105250368B CN105250368B CN201510686721.7A CN201510686721A CN105250368B CN 105250368 B CN105250368 B CN 105250368B CN 201510686721 A CN201510686721 A CN 201510686721A CN 105250368 B CN105250368 B CN 105250368B
- Authority
- CN
- China
- Prior art keywords
- renal failure
- chinese medicine
- medicine composition
- chitosan oligosaccharide
- gypenosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of Chinese medicine composition and preparation method thereof that can delay renal failure, which is made of the component of following parts by weight: 200~300 parts of chitosan oligosaccharide, 20~40 parts of Gypenosides, 160~300 parts of Leonurus extract.The traditional chinese medicine composition of the invention replenishes qi to invigorate the spleen, activating microcirculation and removing stasis medicinal, washs phlegm and drops turbid, inducing diuresis to remove edema, plays the role of dropping urea nitrogen, creatinine, uric acid and blood lipid, can delay renal failure, the azotemia phase for renal insufficiency, it can also be used to hyperuricemia and hyperlipidemia.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, it is related to a kind of Chinese medicine composition that can delay renal failure and its preparation side
Method and application.
Background technique
Renal failure (acute renal failure, ARF) is the clinical critical illness characterized by renal tubular necrosis
Disease, case fatality rate is high, serious danger side of body patient vitals.According to foreign literature over the last couple of decades, the disease incidence of ARF is presented
The trend of liter, ARF patient are still higher than 50% through the case fatality rate of dialysis treatment.At present clinically about the treatment of ARF, mainly by early stage
Patient vitals are saved in haemodialysis, but expense is high, and patient is difficult to bear；And instrument and equipment is expensive, technical level requires high.Very
Extremely, although medical level is being continuously improved, its incidence and the death rate are not apparent from decline over the past decades.Therefore, it finds
Simple and easy to do, cost-effective drug provides new selection for the treatment of ARF patient, is the project for being worth research.
Summary of the invention
The purpose of the present invention is overcome above-mentioned shortcoming to provide a kind of Chinese medicine composition that can delay renal failure.
It is a further object of the present invention to provide the preparation methods of the Chinese medicine composition that can delay renal failure.
The purpose of the present invention is what is be accomplished by the following way:
A kind of Chinese medicine composition that can delay renal failure, the Chinese medicine composition are made of the component of following parts by weight:
200~300 parts of chitosan oligosaccharide
20~40 parts of Gypenosides
160~300 parts of Leonurus extract.
The above-mentioned Chinese medicine composition that can delay renal failure is preferably made of the component of following parts by weight:
200~250 parts of chitosan oligosaccharide
20~40 parts of Gypenosides
160~300 parts of Leonurus extract.
The above-mentioned Chinese medicine composition that can delay renal failure is further preferably made of the component of following parts by weight:
200~250 parts of chitosan oligosaccharide
20~25 parts of Gypenosides
160~200 parts of Leonurus extract.
The above-mentioned Chinese medicine composition that can delay renal failure is most preferably made of the component of following parts by weight:
200 parts of chitosan oligosaccharide
20 parts of Gypenosides
200 parts of Leonurus extract.
It is preferred that molecular weight≤1500 of chitosan oligosaccharide used by the present composition, content >=80%, used strand
Total glycosides content >=80% of Lan, used Leonurus extract are standard proportional extract 10:1.
Chitosan oligosaccharide: Qingdao Bo Zhihui power Biotechnology Co., Ltd；
Gypenosides: Xi'an Si Nuote Bioisystech Co., Ltd；
Leonurus extract: Xi'an Si Nuote Bioisystech Co., Ltd；
Dosage form can be made with pharmaceutically acceptable auxiliary material in the Chinese medicine composition of the present invention that can delay renal failure.
It is preferred that the dosage form is tablet, capsule, granule, oral solution etc..Auxiliary material used can be starch, dextrin, carboxymethyl and form sediment
It is several in powder sodium, sodium carboxymethylcellulose superfine silica gel powder, magnesium stearate, talcum powder, honey element, acesulfame potassium, Opadry etc..
The preparation method of the above-mentioned Chinese medicine composition that can delay renal failure, it is characterised in that this method includes following step
It is rapid: by three kinds of drugs be uniformly mixed to get.
The present composition is mainly made of chitosan oligosaccharide, Gypenosides, Leonurus extract, can effectively delay renal function
Failure reduces urea nitrogen and nonprotein nitrogen in blood.
It is that the present invention can delay the Chinese medicine composition of renal failure major function: replenishing qi to invigorate the spleen, phlegm drop is washed in activating microcirculation and removing stasis medicinal
It is turbid, inducing diuresis to remove edema.Play the role of dropping urea nitrogen, creatinine, uric acid and blood lipid.It can delay renal failure.Nitrogen matter for renal insufficiency
The mass formed by blood stasis phase, it can also be used to hyperuricemia and hyperlipidemia.
Therefore, the above-mentioned Chinese medicine composition that can delay renal failure can delay renal failure in preparation and/or treat gout
It is applied in drug.The above-mentioned Chinese medicine composition that can delay renal failure can also be in preparation drop urea nitrogen, creatinine, uric acid and blood lipid
Drug in apply.
Explanation is further expalined to the present invention below by way of pharmacodynamic test:
The present invention can delay the Chinese medicine composition of renal failure (the preparation method comprises the following steps: by chitosan oligosaccharide, Gypenosides and benefit
The mixture that Brittle Falsepimpernel Herb extract is mixed to get according to the weight ratio of 1 prescription of embodiment, hereinafter referred to as kidney nitrogen are clear), experiment shows
There is apparent reduction to act on serum urea nitrogen, creatinine and uric acid, and have dose-dependence, action intensity is right with the positive
It is suitable according to medicine oxyamyli tectus aldehydum.Our three components have apparent synergistic effect.
Therapeutic effect of the kidney nitrogen clearly to experimental renal failure animal model:
One, experimental method
Using stomach-filling adenine suspension induced rat chronic kidney hypofunction model, 10 rats of control group give 0.5mL/
100g0.5%CMC-Na solution, 110 rats of model group give 5% adenine suspension of 250mg/kg, and the last fortnight fills daily
Stomach, rear stomach-filling every other day in two weeks verified whether modeling succeeds through measurement serum urea nitrogen and creatine concentration after 4 weeks.
Screening animal simultaneously be grouped again, be divided into 12 groups, be respectively as follows: control group (0.5%CMCC-Na solution,
0.5ml/100g), model group (0.5%CMCC-Na solution, 0.5ml/100g), positive drug group (packet formoxy- particle) (2.03g/
Kg/ times), Leonurus extract group (group be divided into Leonurus extract, 0.205g/kg/ times), (group is divided into strand to Gypenosides group
Stock the total glycosides of Lan, 0.1g/kg/ times), chitosan oligosaccharide group (0.325g/kg/ times), chitosan oligosaccharide Gypenosides group (chitosan oligosaccharide and gynostemma pentaphylla
Total glycosides weight ratio 200:20,0.425g/kg/ times), chitosan oligosaccharide Leonurus extract group (chitosan oligosaccharide and Leonurus extract weight
Than 200:200,0.53g/kg/ times), Gypenosides Leonurus extract group (Gypenosides and Leonurus extract weight
Than 20:200,0.305g/kg/ times), the aloof from politics and material pursuits dosage group (1.26g/kg/ times) of kidney nitrogen, the clear middle dose group (0.63g/kg/ of kidney nitrogen
It is secondary), the clear low dose group (0.315g/kg/ times) of kidney nitrogen.Groups of animals number (only) is respectively as follows: 8,8,7,7,7,7,8,8,8,8,8,
8.Twice, the upper and lower noon is each primary, twice administration time interval about 8h for the daily gastric infusion of each group.Kidney nitrogen is aloof from politics and material pursuits, in, low dosage
Group dosage takes 6,3,1.5 times of people's equivalent dosage daily respectively.Chitosan oligosaccharide, Gypenosides, Leonurus extract, shell are few
Sugared Gypenosides, chitosan oligosaccharide Leonurus extract, Gypenosides Leonurus extract group dosage and the clear middle dose group of kidney nitrogen
It is identical.The daily administration dosage of positive drug group takes 3 times or so of the equivalent dosage of people, identical as kidney nitrogen agent group middle clearly.Before administration, even
Continuous administration detected serum urea nitrogen (BUN), creatinine (CRE) concentration after 2 weeks respectively.In addition, being put to death after successive administration 5 weeks dynamic
Object takes serum and renal tissue, in addition to detecting serum BUN, CRE, then detects uric acid in serum, hemoglobin, albumin concentration,
And reductive glutathione (GSH), r- glutamyl transferase (r-GT), malonaldehyde (MAD), glutathione peroxide in nephridial tissue
Compound enzyme (GSH-PX), total number born (SOD) content.Statistics detection is detected with one-way analysis of variance LSD.
Two, kidney nitrogen clearly analyzes the amount-result relation of experimental renal failure therapeutic effect
It the results are shown in Table 1, table 2.Compared with model group, serum BUN, CRE testing result show kidney nitrogen it is aloof from politics and material pursuits, in, low dosage
Administration group, which is shown, increases apparent inhibiting effect to two indexes, and has administration time dependence, with the successive administration time
Extend, depression effect increases.Serum and nephridial tissue Indexs measure after successive administration 5 weeks the result shows that, the clear Inhibition test of kidney nitrogen
Renal failure effect also has dosage dependence；In addition to serum uric acid concentration and nephridial tissue MDA content, other index high dose groups
Improvement result be significantly greater than low dose group, the improvement result of some indexs is also greater than middle dose group, and there are also indexs
Improvement result middle dose group is greater than low dose group.Serum uric acid concentration and the improvement result of nephridial tissue MDA content not show dose
Correlation, may with the two indexs are practical in three administration groups restore that related (and Normal group approaches even more
It is small).Positive drug (packet formoxy- particle) group also shows apparent therapeutic effect, but increases serum uric acid without reducing effect；Deng
Dosage administration (the clear middle dose group of kidney nitrogen is compared with positive drug group) is imitated, the clear curative effect of kidney nitrogen and positive drug are close, but have feature: right
Serum BUN, uric acid improvement result kidney nitrogen be better than positive drug clearly, positive drug is lower than clearly to the improvement result kidney nitrogen of nephridial tissue GSH.
Two, kidney nitrogen clearly analyzes the prescription rationality of experimental renal failure therapeutic effect
It the results are shown in Table 3, table 4.In experiment, chitosan oligosaccharide, Gypenosides, Leonurus extract, chitosan oligosaccharide Gypenosides,
The clear middle dosage administration group chitosan oligosaccharide of chitosan oligosaccharide Leonurus extract, Gypenosides Leonurus extract, kidney nitrogen, gynostemma pentaphyllum total
The respective dosage of glycosides, Leonurus extract is respectively 0 or equal, and the clear prescription compatibility of medicines of kidney nitrogen can be illustrated by pretending statistics between group and comparing
Reasonability.The result shows that most serum and nephridial tissue biochemical indicator testing result, the clear middle dosage of kidney nitrogen after successive administration 5 weeks
The improvement result of group is better than chitosan oligosaccharide, Gypenosides, Leonurus extract, chitosan oligosaccharide Gypenosides, chitosan oligosaccharide motherwort
Extract, Gypenosides Leonurus extract administration group prompt kidney nitrogen to organize composition and division in a proportion chitosan oligosaccharide, Gypenosides, motherwort clearly
Extract is individually or combination of two is more preferable to the therapeutic effect of experimental renal failure.Serum and nephridial tissue are biochemical after successive administration 5 weeks
2 × 2 × 2 variance analysis reciprocation testing result of index shows: to the improvement result of BUN, CRE, SOD, chitosan oligosaccharide, gynostemma pentaphylla
Total glycosides, Leonurus extract have a significant effect (P < 0.05 or P < 0.01), and chitosan oligosaccharide × Gypenosides, chitosan oligosaccharide × benefit are female
Careless extract, Gypenosides × Leonurus extract without reciprocation (P > 0.05), chitosan oligosaccharide × Gypenosides ×
Leonurus extract is also without reciprocation (P > 0.05)；To the improvement result of uric acid, chitosan oligosaccharide, Gypenosides, motherwort
Extract has a significant effect (whole P < 0.01), and chitosan oligosaccharide × Gypenosides, chitosan oligosaccharide × Leonurus extract have interaction
(<0.04), Gypenosides × Leonurus extract does not have reciprocation (P>0.05), chitosan oligosaccharide × strand by P<0.01, P for effect
Total glycosides × the Leonurus extract of Lan has reciprocation (P < 0.01), due to serum uric acid each group substantially restore (with compare
Group is close), therefore testing result does not have special biological significance；To the improvement result of hemoglobin concentration, chitosan oligosaccharide, gynostemma pentaphyllum total
Glycosides has a significant effect (P < 0.01, P < 0.05), and Leonurus extract has an impact (P < 0.1), and chitosan oligosaccharide × Gypenosides, shell are few
Sugar × Leonurus extract, chitosan oligosaccharide × Gypenosides × Leonurus extract are without reciprocation (P > 0.05)；Dialogue
The improvement result of protein concentration, chitosan oligosaccharide, Gypenosides, Leonurus extract have a significant effect (P < 0.01 or P <
0.05), chitosan oligosaccharide × Gypenosides have obvious reciprocation (P < 0.05), chitosan oligosaccharide × Leonurus extract, gynostemma pentaphyllum total
Glycosides × Leonurus extract, chitosan oligosaccharide × Gypenosides × Leonurus extract are without reciprocation (P > 0.05)；To GSH
Improvement result, chitosan oligosaccharide, Gypenosides, Leonurus extract have a significant effect (whole P < 0.01), chitosan oligosaccharide × strand
The total glycosides of stock Lan, chitosan oligosaccharide × Leonurus extract do not have reciprocation (P > 0.05), Gypenosides × Leonurus extract, shell
Oligosaccharides × Gypenosides × Leonurus extract has reciprocation (P < 0.05), shows chitosan oligosaccharide, Gypenosides, motherwort
Extract has synergistic effect to GSH is improved；To the improvement result of γ-GT, chitosan oligosaccharide, Gypenosides, Leonurus extract are equal
Have a significant effect (whole P < 0.01), and chitosan oligosaccharide × Gypenosides have reciprocation (P < 0.01), and chitosan oligosaccharide × motherwort mentions
Object, Gypenosides × Leonurus extract is taken not to have reciprocation (P > 0.05), chitosan oligosaccharide × Gypenosides × motherwort
Extract has reciprocation (P < 0.01), shows that chitosan oligosaccharide, Gypenosides, Leonurus extract have collaboration to γ-GT is improved
Effect；To the improvement result of MDA, chitosan oligosaccharide, Gypenosides, Leonurus extract have a significant effect (whole P < 0.01),
Gypenosides × Leonurus extract has reciprocation (P < 0.01), and chitosan oligosaccharide × Leonurus extract, Gypenosides ×
Leonurus extract, chitosan oligosaccharide × Gypenosides × Leonurus extract do not have reciprocation (P > 0.05), show chitosan oligosaccharide,
Gypenosides, Leonurus extract have synergistic effect to γ-GT is improved；To the improvement result of GSH-PX, only chitosan oligosaccharide has
It influences (P<0.1), without influencing (P>0.05), Gypenosides × motherwort is extracted for Gypenosides, Leonurus extract
Object, chitosan oligosaccharide × Leonurus extract, Gypenosides × Leonurus extract, chitosan oligosaccharide × Gypenosides × motherwort mention
It takes object without reciprocation (P > 0.05), shows that chitosan oligosaccharide is most important to the improvement result of GSH-PX, but chitosan oligosaccharide, twist
The total glycosides of stock Lan, Leonurus extract do not act synergistically in the clear prescription of composition kidney nitrogen.
In summary it analyzes, the clear prescription of kidney nitrogen is reasonable.Chitosan oligosaccharide, Gypenosides, Leonurus extract composition are multiple
Fang Houke plays synergistic effect to the therapeutic effect of experimental renal failure, especially to experimental renal failure model nephridial tissue GSH, γ-GT
Improvement have synergistic effect.In three factors, the effect of chitosan oligosaccharide is better than Gypenosides and Leonurus extract.
Specific embodiment
Below by way of specific embodiment, invention is further explained:
1 kidney nitrogen clearing capsule of embodiment
Preparation method: three kinds of drugs being uniformly mixed with starch, are mixed with starch, fill capsule, every 0.5g to get.
Usage and dosage: it is oral, 3 times a day, once two grains.
The 2 clear piece of kidney nitrogen of embodiment
Preparation method: three kinds of drugs are uniformly mixed with starch, the ethyl alcohol system for being 70%--90% with appropriate mass concentration
It is grain, dry, add 1.5% magnesium stearate, mix, tabletting, every 0.6g to get.Usage and dosage: it is oral, 3 times a day, one time 2
Piece.
The 3 clear particle of kidney nitrogen of embodiment
Preparation method: three kinds of drugs being mixed and dextrin, aspartame are uniform, with appropriate 70%--90% alcohol granulation,
It is dry, packing, every packet 3g to get.Usage and dosage: it is oral, 3 times a day, one time 1 packet.
Claims (9)
1. a kind of Chinese medicine composition that can delay renal failure, it is characterised in that the Chinese medicine composition by following parts by weight group
Divide and be made:
200~250 parts of chitosan oligosaccharide
20~40 parts of Gypenosides
160~300 parts of Leonurus extract.
2. the Chinese medicine composition according to claim 1 that renal failure can be delayed, it is characterised in that the chitosan oligosaccharide
Molecular weight≤1500, content >=80%.
3. the Chinese medicine composition according to claim 1 that renal failure can be delayed, it is characterised in that the gynostemma pentaphylla
Total glycosides content >=80%.
4. the Chinese medicine composition according to claim 1 that renal failure can be delayed, it is characterised in that the motherwort
Extract is standard proportional extract 10:1.
5. the Chinese medicine composition according to claim 1 or 2 that renal failure can be delayed, it is characterised in that the composition with
Dosage form is made in pharmaceutically acceptable auxiliary material.
6. the Chinese medicine composition according to claim 5 that renal failure can be delayed, it is characterised in that the dosage form is
Tablet, capsule, granule.
7. the preparation method of the Chinese medicine composition described in claim 1 that renal failure can be delayed, it is characterised in that this method
The following steps are included: by three kinds of drugs be uniformly mixed to get.
8. the Chinese medicine composition described in claim 1 that can delay renal failure delays renal failure and/or treatment gout in preparation
Drug in application.
9. the medicine that urea nitrogen, creatinine, uric acid drop in preparation in the Chinese medicine composition described in claim 1 that can delay renal failure
Application in object.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510686721.7A CN105250368B (en) | 2015-10-21 | 2015-10-21 | It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510686721.7A CN105250368B (en) | 2015-10-21 | 2015-10-21 | It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105250368A CN105250368A (en) | 2016-01-20 |
| CN105250368B true CN105250368B (en) | 2019-11-08 |
Family
ID=55090504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510686721.7A Active CN105250368B (en) | 2015-10-21 | 2015-10-21 | It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105250368B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105837706A (en) * | 2016-03-23 | 2016-08-10 | 卞毓平 | Extraction method of chitin and chitin product |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656276A (en) * | 2013-11-27 | 2014-03-26 | 潍坊市现代风湿病研究院 | Medicine for treating renal failure and preparation method of medicine |
| CN104839673A (en) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Medical formula food for people with renal failure |
-
2015
- 2015-10-21 CN CN201510686721.7A patent/CN105250368B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103656276A (en) * | 2013-11-27 | 2014-03-26 | 潍坊市现代风湿病研究院 | Medicine for treating renal failure and preparation method of medicine |
| CN104839673A (en) * | 2015-04-13 | 2015-08-19 | 劲膳美生物科技股份有限公司 | Medical formula food for people with renal failure |
Non-Patent Citations (2)
| Title |
|---|
| 壳寡糖对ARF兔肾的保护作用及其血液流变学的影响;王顺蓉等;《四川动物》;20130728(第04期);第602页左边栏第4段-第604页右边栏第1段 * |
| 益母草防治急性肾功能衰竭的试验;张峻等;《基层中药杂志》;20000415;第14卷(第2期);第12页左边栏第2段-右边栏第3段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105250368A (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239069A (en) | Application of compound capable of supplying active methyl or engaging in methyl migration | |
| CN104922176B (en) | A kind of application of Flos Chrysanthemi Indici extract | |
| TWI269656B (en) | Therapeutical composition for hepatitis C | |
| US10821149B2 (en) | Composition and the use thereof | |
| RU2372900C2 (en) | Inhibitor of contraction and development of liver cancer to be applied in hepatitis c positive patients suffering from cirrhosis | |
| CN100418562C (en) | Medicinal composition, its preparing method and quality controlling means | |
| CN101879264A (en) | Chinese medicinal composition for reducing blood uric acid | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| CN104069391B (en) | A kind of Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof | |
| CN105250368B (en) | It is a kind of to delay Chinese medicine composition of renal failure and its preparation method and application | |
| JP2007161675A (en) | Fatigue-improving internal medicine | |
| CN103830374B (en) | The application in hyperuricemia clearly of three leaf glycolipids | |
| CN107753669A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect and preparation method thereof and purposes | |
| CN107753708A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect and preparation method thereof and purposes | |
| Goto et al. | Clinical evaluation of the effect of daio (rhei rhizoma) on the progression of diabetic nephropathy with overt proteinuria | |
| CN104546987A (en) | Application of gynostemma pentaphyllum total saponins to prevention and cure of hyperuricemia | |
| CN1331466C (en) | Medicine preparation for treating liver and gallbladder disease and its preparing process | |
| CN106349318A (en) | Application of pentacyclic triterpene compounds to preparation of medicine for treating adiposis | |
| CN104857095A (en) | Application of traditional Chinese medicine composition, for preparing medicines for treating cholestatic jaundice | |
| CN104643058A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicines for improving or/and treating liver cirrhosis diseases | |
| CN109481469A (en) | Application of the drug and colla carapacis et plastri testudinis of a kind of colla carapacis et plastri testudinis treatment gout in preparation treatment gout drug | |
| CN107753673A (en) | A kind of pharmaceutical composition with anti-trioxypurine effect and preparation method thereof and purposes | |
| CN110898170B (en) | Traditional Chinese medicine composition for treating metabolic syndrome and preparation thereof | |
| JP2006213607A (en) | Uric acid value-decreasing agent | |
| CN102475784B (en) | Chinese medicinal composition for treating essential hypertension and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |